Neuraxpharm and API specialist Inke part with help of private equity company

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images

Related tags API Active pharmaceutical ingredients Manufacturing Supply chain Divestment

Neuraxapharm Group, a European-based pharmaceutical company that focuses on central nervous system (CNS) announced last week that it had signed a binding agreement to divest API developer and manufacturer company, Inke, to private equity manager Keensight Capital.

The company says the decision will allow it to focus more on its core CNS therapeutic area and for Inke to accelerate its development as an independent entity.

Established in 1980 and based in Spain, Inke, says it is the partner of choice for inhalation APIs. The company combines more than 20 years of in-house experience in micronization and particle engineering with complex synthesis processes and high regulatory expertise. It has established preferential relationships with major pharmaceutical companies worldwide, including in key markets such as the US and the EU, as well as the highly regulated Japanese market.

Neuraxpharm says its decision to divest Inke allows the group ‘to sharpen its focus on becoming a leader in its core business of CNS disorders as it solidifies its position in Europe and continues to expand its global footprint’.

Keensight Capital will support Inke’s team, led by Miquel Bachs, in its next phase of growth. The private equity company will support Inke notably by helping to expand its footprint, broaden its offering, grow its product portfolio, and attract complementary professionals. Keensight expects to be able to leverage its extensive knowledge, expertise, and network in the pharmaceutical industry, in order to achieve these goals.

Jörg-Thomas Dierks, CEO of Neuraxpharm, added: “This transaction is beneficial for all parties. Inke, its customers and employees will benefit from Keensight Capital’s expertise and investment track record in the healthcare sector.

“The new owner gets a highly differentiated specialist with a focus on micronized APIs for inhalation drugs, a high-growth segment of the market with strong entry barriers, while at Neuraxpharm we can continue to execute on our strategy of further solidifying our leading European market positioning in treating CNS disorders. We wish the whole Inke team all the best for this exciting new chapter of their success story.”

Miquel Bachs, general manager of Inke, said: “As we begin our journey with Keensight Capital we would like to thank the team at Neuraxpharm for their support throughout our successful relationship. We are excited and optimistic about the next growth phase for Inke as we make continued progress in the inhalation API sector.”

Amit Karna, Partner at Keensight Capital, added: “Inke’s positioning as a specialist in micronized APIs perfectly fits our strategy of investing in highly profitable, fast-growing leaders in niche segments.” and Javier López Moras, Partner at Keensight Capital, added: “We look forward to partnering with Miquel and Inke management in helping the company reach its full potential as an independent entity.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us